Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
GROUP A: Valsartan plus Chlorthalidone
GROUP B: Valsartan
GROUP C: Chlorthalidone
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension, High blood pressure, Drug therapy combination, Valsartan, Chlorthalidone, Safety, Efficacy
Eligibility Criteria
Inclusion Criteria:
- Patient with diagnosis of arterial hypertension defined as:
- Systolic blood pressure greater or equal to 140 and lower than 180 mmHg
- Diastolic blood pressure greater or equal to 90 and lower than 110 mmHg
- Non controlled patients with antihypertensive treatment (blood pressure values: Systolic blood pressure > 140 mmHg and/or Diastolic blood pressure > 90 mmHg) or patients antihypertensive treatment-naïve.
- Likelihood of attending consultations according to the trial chronogram.
- Informed Consent Signature.
Exclusion Criteria:
- Diagnosis of severe or malignant arterial hypertension defined as:
- Systolic blood pressure greater or equal to 180 mmHg
- Diastolic blood pressure greater or equal to 110 mmHg
- Patients with secondary arterial hypertension of any etiology.
- Pregnant women or women with childbearing potential who are not using appropriate contraception methods; women planning to become pregnant during the trial.
- Patients with history of Acute Myocardial Infarction o Angina Pectoris within the 6 months prior to the trial initiation.
- Diagnosis of Cerebrovascular Disease (CVD) o Transient Ischemic Attack (TIA) within the 6 previous months.
- Patients with Severe Renal Disease defined by serum Creatinine levels higher than 1.5 mg/dl.
- Diagnosed or suspected unilateral or bilateral renal artery stenosis.
- History of non remitting cancer within the 5 years prior to the trial initiation.
- Patients with Hypokalemia or Hyperkalemia.
- Patients receiving Valsartan or Chlortalidone during the 14 previous days.
- Patients with known hypersensitivity to Valsartan or Chlorthalidone.
- Unstable patients with antecedent of hospitalization within the 4 days prior to their enrollment in the trial.
- Patients with history of drugs and alcohol abuse within the last year.
- Patients who have taken part in other clinical trial within the 4 weeks prior to the initiation of this research.
- Patients with any other clinical condition that the investigator deems may affect the patient follow-up.
Sites / Locations
- Centro de Diagnostico Cardiologico
- Fundacion Cardiomet Cequin
- MedPlus
- Centro AMCOR
- Centro Clinico quirurgico
- Centro médico de hipertensión arterial
- Clínica DAME
- Consultorio Edificio Novoa
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
GROUP A: Valsartan plus Chlorthalidone
GROUP B: Valsartan
GROUP C: Chlorthalidone
Arm Description
GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.
GROUP B: Treatment with Monotherapy. Valsartan 80 mg. Once daily during 12 weeks.
GROUP C: Treatment with Monotherapy. Chlorthalidone 12,5 mg. Once daily during 12 weeks.
Outcomes
Primary Outcome Measures
Safety and Efficacy of the fixed-dose combination treatment with Valsartan plus Chlorthalidone
Efficacy and safety of a fixed-dose combination treatment of Valsartan plus Chlorthalidone Vs Valsartan or Chlorthalidone alone in the treatment of patients with arterial hypertension
Secondary Outcome Measures
Changes in Systolic and Diastolic Blood pressure values
Assess the changes in Systolic and Diastolic Blood Pressure from baseline up to week 12
Changes of Systolic blood pressure values
Assess the changes of systolic blood pressure from baseline up to week 6 and 12
Changes of Diastolic blood pressure values
Assess the changes of diastolic blood pressure from baseline up to week 6 and 12
Changes of diastolic blood pressure in arterial blood pressure median values
Assess the changes in diastolic blood pressure in Arterial Blood Pressure Media from baseline up to week 12
Changes of systolic blood pressure values in arterial blood pressure median values
Assess the change in systolic blood pressure in Arterial Blood Pressure Median from baseline up to week 12
Patient that achieving blood pressure values lower than 140/90 (systolic/diastolic) at week 6 and 12
Determine the percentage of patients achieving blood pressure values lower than 140/90 (systolic/diastolic) at weeks 6 and 12
Patients that achieving systolic blood pressure values lower than 140 at week 6 and 12
Determine the percentage of patients achieving systolic blood pressure lower than 140 at weeks 6 and 12
Patients that achieving diastolic blood pressure values lower than 90 at week 6 and 12
Determine the percentage of patients achieving diastolic blood pressure lower than 90 at week 6 and 12
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01850160
Brief Title
Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension
Official Title
Efficacy and Safety of the Fixed-dose Combination of Valsartan Plus Chlorthalidone Vs Valsartan or Chlorthalidone Alone in the Treatment of Arterial Hypertension, Open-label, Controlled, Randomized and Multicenter Trial
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
April 2013 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
May 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Farma de Colombia SA
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial is aimed to assess the efficacy and safety of a fixed-dose combination therapy with Valsartan and Chlorthalidone, Vs Valsartan or Chlorthalidone alone for treatment of adult patients with diagnosis of arterial hypertension.
Detailed Description
In spite of the existence of a great variety of treatments with drugs effective against arterial hypertension, the percentages of arterial hypertension control with monotherapy remain quite low reason why the fixed-dose combinations of drugs have been one of the most interesting research topics in order to achieve an appropriate control of arterial hypertension.
The possibility of achieving better coverage and Blood Pressure control through a drug combination has leaded, on a scientific base of the efficacy of an Angiotensin Receptor Blockers II plus diuretic combination, to the development of a great number of combinations with different Angiotensin II Receptor Blockers plus hydrochlorothiazide. Yet it is noteworthy that despite the increasing evidence showing additional benefits in Blood pressure control and reduction of cardiovascular outcomes with chlorthalidone over hydrochlorothiazide, there is neither a great number of combinations nor studies with Angiotensin II Receptor Blockers plus chlorthalidone whereby the conduction of a trial assessing the efficacy and safety of Valsartan plus chlorthalidone in hypertensive patients is proposed plus the benefits of combination therapy that include, among others, the greater efficacy with lower doses of each individual component as well as reduction in occurrence of adverse events directly related with lower drug doses.With this treatment schedule it is expected to obtain higher control of blood pressure values and greater percentage of patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, High blood pressure, Drug therapy combination, Valsartan, Chlorthalidone, Safety, Efficacy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
124 (Actual)
8. Arms, Groups, and Interventions
Arm Title
GROUP A: Valsartan plus Chlorthalidone
Arm Type
Experimental
Arm Description
GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.
Arm Title
GROUP B: Valsartan
Arm Type
Experimental
Arm Description
GROUP B: Treatment with Monotherapy. Valsartan 80 mg. Once daily during 12 weeks.
Arm Title
GROUP C: Chlorthalidone
Arm Type
Experimental
Arm Description
GROUP C: Treatment with Monotherapy. Chlorthalidone 12,5 mg. Once daily during 12 weeks.
Intervention Type
Drug
Intervention Name(s)
GROUP A: Valsartan plus Chlorthalidone
Other Intervention Name(s)
Chlorthalidone Drug Combination, Valsartan Drug Combination, Antihypertensive Agents
Intervention Description
Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
Intervention Type
Drug
Intervention Name(s)
GROUP B: Valsartan
Other Intervention Name(s)
Angiotensin II Receptor Antagonist, Antihypertensive Agents
Intervention Description
GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
Intervention Type
Drug
Intervention Name(s)
GROUP C: Chlorthalidone
Other Intervention Name(s)
Sodium Chloride Symporter Inhibitors, Antihypertensive Agents, Diuretics
Intervention Description
GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
Primary Outcome Measure Information:
Title
Safety and Efficacy of the fixed-dose combination treatment with Valsartan plus Chlorthalidone
Description
Efficacy and safety of a fixed-dose combination treatment of Valsartan plus Chlorthalidone Vs Valsartan or Chlorthalidone alone in the treatment of patients with arterial hypertension
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Changes in Systolic and Diastolic Blood pressure values
Description
Assess the changes in Systolic and Diastolic Blood Pressure from baseline up to week 12
Time Frame
12 weeks
Title
Changes of Systolic blood pressure values
Description
Assess the changes of systolic blood pressure from baseline up to week 6 and 12
Time Frame
12 weeks
Title
Changes of Diastolic blood pressure values
Description
Assess the changes of diastolic blood pressure from baseline up to week 6 and 12
Time Frame
12 weeks
Title
Changes of diastolic blood pressure in arterial blood pressure median values
Description
Assess the changes in diastolic blood pressure in Arterial Blood Pressure Media from baseline up to week 12
Time Frame
12 weeks
Title
Changes of systolic blood pressure values in arterial blood pressure median values
Description
Assess the change in systolic blood pressure in Arterial Blood Pressure Median from baseline up to week 12
Time Frame
12 weeks
Title
Patient that achieving blood pressure values lower than 140/90 (systolic/diastolic) at week 6 and 12
Description
Determine the percentage of patients achieving blood pressure values lower than 140/90 (systolic/diastolic) at weeks 6 and 12
Time Frame
12 weeks
Title
Patients that achieving systolic blood pressure values lower than 140 at week 6 and 12
Description
Determine the percentage of patients achieving systolic blood pressure lower than 140 at weeks 6 and 12
Time Frame
12 weeks
Title
Patients that achieving diastolic blood pressure values lower than 90 at week 6 and 12
Description
Determine the percentage of patients achieving diastolic blood pressure lower than 90 at week 6 and 12
Time Frame
12 weeks
Other Pre-specified Outcome Measures:
Title
Metabolic changes secondary to the treatment with Valsartan and Chlorthalidone, Vs Valsartan or Chlorthalidone
Description
Identify if there are significant differences regarding metabolic changes secondary to the treatment with Valsartan and Chlorthalidone Vs Valsartan or Chlorthalidone.
Time Frame
12 weeks
Title
Incidence of adverse events in each intervention group
Description
Determine the percentage of incidence of adverse events in each intervention group.
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with diagnosis of arterial hypertension defined as:
Systolic blood pressure greater or equal to 140 and lower than 180 mmHg
Diastolic blood pressure greater or equal to 90 and lower than 110 mmHg
Non controlled patients with antihypertensive treatment (blood pressure values: Systolic blood pressure > 140 mmHg and/or Diastolic blood pressure > 90 mmHg) or patients antihypertensive treatment-naïve.
Likelihood of attending consultations according to the trial chronogram.
Informed Consent Signature.
Exclusion Criteria:
Diagnosis of severe or malignant arterial hypertension defined as:
Systolic blood pressure greater or equal to 180 mmHg
Diastolic blood pressure greater or equal to 110 mmHg
Patients with secondary arterial hypertension of any etiology.
Pregnant women or women with childbearing potential who are not using appropriate contraception methods; women planning to become pregnant during the trial.
Patients with history of Acute Myocardial Infarction o Angina Pectoris within the 6 months prior to the trial initiation.
Diagnosis of Cerebrovascular Disease (CVD) o Transient Ischemic Attack (TIA) within the 6 previous months.
Patients with Severe Renal Disease defined by serum Creatinine levels higher than 1.5 mg/dl.
Diagnosed or suspected unilateral or bilateral renal artery stenosis.
History of non remitting cancer within the 5 years prior to the trial initiation.
Patients with Hypokalemia or Hyperkalemia.
Patients receiving Valsartan or Chlortalidone during the 14 previous days.
Patients with known hypersensitivity to Valsartan or Chlorthalidone.
Unstable patients with antecedent of hospitalization within the 4 days prior to their enrollment in the trial.
Patients with history of drugs and alcohol abuse within the last year.
Patients who have taken part in other clinical trial within the 4 weeks prior to the initiation of this research.
Patients with any other clinical condition that the investigator deems may affect the patient follow-up.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Juan D Romero, MD
Organizational Affiliation
Farma de Colombia SA
Official's Role
Study Director
Facility Information:
Facility Name
Centro de Diagnostico Cardiologico
City
Cartagena
State/Province
Bolivar
ZIP/Postal Code
130001
Country
Colombia
Facility Name
Fundacion Cardiomet Cequin
City
Armenia
State/Province
Quindio
ZIP/Postal Code
630001
Country
Colombia
Facility Name
MedPlus
City
Bogota DC
ZIP/Postal Code
11001
Country
Colombia
Facility Name
Centro AMCOR
City
Quito
ZIP/Postal Code
EC170150
Country
Ecuador
Facility Name
Centro Clinico quirurgico
City
Quito
ZIP/Postal Code
EC170150
Country
Ecuador
Facility Name
Centro médico de hipertensión arterial
City
Quito
ZIP/Postal Code
EC170150
Country
Ecuador
Facility Name
Clínica DAME
City
Quito
ZIP/Postal Code
EC170150
Country
Ecuador
Facility Name
Consultorio Edificio Novoa
City
Quito
ZIP/Postal Code
EC170150
Country
Ecuador
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
30202211
Citation
Manzur F, Rico A, Romero JD, Rodriguez-Martinez CE. Efficacy and Safety of Valsartan or Chlorthalidone vs. Combined Valsartan and Chlorthalidone in Patients With Mild to Moderate Hypertension: The VACLOR Study. Clin Med Insights Cardiol. 2018 Sep 3;12:1179546818796482. doi: 10.1177/1179546818796482. eCollection 2018.
Results Reference
derived
Learn more about this trial
Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension
We'll reach out to this number within 24 hrs